Telix Pharmaceuticals (Telix) reported FY 2025 revenue from contracts with customers of USD 803.79 million (+56%), with gross profit of USD 426.44 million and operating profit of USD 29.78 million. The company posted a loss for the year attributable to owners of USD 7.12 million, compared with a profit in FY 2024, while total comprehensive loss was USD 14.12 million. Adjusted EBITDA was USD 39.55 million (down 41%), and cash and cash equivalents were USD 141.9 million at December 31, 2025. By segment, Precision Medicine revenue from contracts with customers was USD 621.93 million, with operating profit of USD 209.55 million and Adjusted EBITDA of USD 216.43 million (+24%). Therapeutics revenue from contracts with customers was USD 9.27 million, while Adjusted EBITDA was a loss of USD 98.0 million. Manufacturing Solutions revenue from contracts with customers was USD 172.59 million, and Adjusted EBITDA was a loss of USD 21.72 million. Telix said FY 2025 performance was driven by commercial sales of its prostate cancer imaging agents Illuccix and, in 2025, Gozellix, alongside eleven months of revenue from RLS, acquired January 28, 2025. The company highlighted pipeline progress including TLX591-Tx in a Phase 3 trial (ProstACT Global), and imaging candidates TLX250-Px (kidney cancer) and TLX101-Px (glioma). It also noted preparation for re-submission of two new imaging agents to the FDA, inventory build for commercial launches, and spending to support the launches of Gozellix in the U.S. and Illuccix in Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-009943), on February 20, 2026, and is solely responsible for the information contained therein.